远大医药(00512.HK)发布公告，集团用于治疗蠕形螨睑缘炎的全球创新眼科药物 GPN01768 (TP-03，洛替拉纳滴眼液，0.25%)近日获得中国澳门特别行政区政府药物监督管理局 (澳门药监局)批准上市，这是集团在眼科治疗创新领域的又一项重要进展。该产品在澳门药监局获批为未来在粤港澳大湾区的获批奠定了基础，也有望进一步促进其在中国大陆的落地。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.